Celiprolol is a selective adrenoceptor modulator that acts not only as a selective β₁ receptor antagonist, but also as a β₂ receptor partial agonist. Because of its of its β₂ agonist activity, celiprolol lacks the typical side effects of the beta-blockers, such as bronchoconstriction, depression of left ventricular function, and peripheral vasoconstriction, making it a good candidate for patients with both cardiovascular and pulmonary disease. It is currently being investigated for treatment of vascular Ehlers-Danlos Syndrome (vEDS).